GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Apollon Formularies PLC (AQSE:APOL) » Definitions » Long-Term Debt

Apollon Formularies (AQSE:APOL) Long-Term Debt : £0.00 Mil (As of Jun. 2023)


View and export this data going back to . Start your Free Trial

What is Apollon Formularies Long-Term Debt?

Apollon Formularies's Long-Term Debt for the quarter that ended in Jun. 2023 was £0.00 Mil.


Apollon Formularies Long-Term Debt Historical Data

The historical data trend for Apollon Formularies's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apollon Formularies Long-Term Debt Chart

Apollon Formularies Annual Data
Trend Jun10 Jun11 Dec12 Dec13 Dec14 Dec17 Dec18 Dec19 Dec20 Dec21
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Apollon Formularies Semi-Annual Data
Jun11 Jun12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec17 Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Jun23
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Apollon Formularies  (AQSE:APOL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Apollon Formularies Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Apollon Formularies's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Apollon Formularies (AQSE:APOL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
6 Hope Street, Quayside House, Castletown, IMN, IM9 1AS
Apollon Formularies PLC is a London, England and Jamaican based medical cannabis pharmaceutical company specialising in research and treatment of patients with cancer and chronic pain. It is engaged in investing by seeking to acquire a direct and/or indirect interest in projects and assets in the agriculture and logistics sectors and the medicinal cannabis sector. The company focus on opportunities in Africa and Europe. It has created proprietary hybrid medical cannabis pharmaceutical strains, technology, formulations, and treatment products.

Apollon Formularies (AQSE:APOL) Headlines

From GuruFocus

7 Arbitrage Trades With High Profit Potential

By Jonathan Poland Jonathan Poland 11-30-2016

FPA Capital Comments on Apollo Education

By Holly LaFon Holly LaFon 01-30-2017

FPA Capital Fund 4th Quarter 2015 Commentary

By Holly LaFon Holly LaFon 02-08-2016

FPA Capital Fund Comments on For-Profit Education Stocks

By Holly LaFon Holly LaFon 12-09-2015

Weekly Guru Bargains Highlights: APOL, GNW, BTU, NIHD, OKE

By GuruFocus GuruFocus 06-30-2012

FPA Capital Fund new buys in Q2 2015

By Tiziano Frateschi Tiziano Frateschi 07-14-2015

Yacktman Fund Comments on Apollo

By Holly LaFon Holly LaFon 02-05-2016

5-Star Predictable Companies with Highest ROA

By Holly LaFon Holly LaFon 03-20-2012

Yacktman Funds Comments on Apollo Group

By Holly LaFon Holly LaFon 03-13-2013

The Yacktman Focused Fund's Top Growth Stocks

By Dianne Tordillo Dianne Tordillo 01-25-2013